The Cognitive and Research Center of New Jersey

Springfield, New Jersey 07801

5 studies enrolling now · 25 studies all time

What they study most

AD, Alzheimer Disease, Alzheimer Disease (AD), Alzheimer Disease 1, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17

Studies at this site

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Recruiting now
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Recruiting now
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Running, not enrolling
• A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease — Running, not enrolling
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) — Enrolling by invitation
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance — Stopped early
• Multi-Center Study of Sensory Stimulation to Improve Brain Function — Running, not enrolling
• A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials — Completed